Discovery of the Genetic Basis of Childhood Cancers and of Structural Birth Defects: Gabriella Miller Kids First Pediatric Research Program (X01 Clinical Trial Not Allowed)
ID: 351450Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
    Description

    The National Institutes of Health (NIH) is inviting applications for the Gabriella Miller Kids First Pediatric Research Program, aimed at discovering the genetic basis of childhood cancers and structural birth defects through whole genome sequencing of pediatric cohorts. The program seeks to enhance understanding of the genetic contributions to these conditions, encouraging proposals that focus on underrepresented racial and ethnic groups to enrich the Kids First Data Resource Center with diverse genomic and clinical data. This funding opportunity is critical for advancing collaborative research that can lead to improved healthcare outcomes for affected children and families, with applications due by March 13, 2024. For further details, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-24-082.html.

    Point(s) of Contact
    Files
    Title
    Posted
    The Notice of Funding Opportunity (NOFO) from the Department of Health and Human Services invites applications to support the Gabriella Miller Kids First Pediatric Research Program. This initiative emphasizes the exploration of genetic contributions to childhood cancers and structural birth defects through whole genome sequencing of pediatric cohorts. The program encourages diversity in study populations, particularly focusing on underrepresented racial and ethnic groups, to enhance the Kids First Data Resource Center with valuable genomic and clinical data. Submissions are open for various sequencing methods, including whole genome, exome, and transcriptome sequencing. The funding is designed for researchers to prepare cohorts for sequencing within a year without providing financial support for additional data collection or analyses. The NOFO outlines various eligibility criteria for applicants from academia, nonprofits, local governments, and international organizations. Key dates for application submissions begin February 13, 2024, with a final expiration on March 14, 2024. The overarching goal is to facilitate collaborative research that leads to advancements in understanding and treating childhood conditions, aligning with the needs for comprehensive data sharing as established by NIH policies. The NOFO emphasizes rigorous and responsible research practices while aiming to improve healthcare outcomes for affected children and families.
    Similar Opportunities
    Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric Research Data (R03 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering small research grants under the Gabriella Miller Kids First Pediatric Research Program, aimed at analyzing genomic and phenotypic data related to childhood cancers and structural birth defects. This funding opportunity encourages innovative research projects that utilize Kids First data, with a focus on developing analytical approaches, tools, or algorithms to enhance understanding and treatment of pediatric conditions. The initiative is part of a broader effort to leverage genomics for precision medicine in pediatric healthcare, with a maximum funding amount of $200,000 available for projects lasting up to two years. Interested applicants can find more information and apply by visiting the program's webpage or contacting NIH Grants Information at grantsinfo@nih.gov, with applications due by January 7, 2026.
    Gabriella Miller Kids First Training and Outreach Core (U24 Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing an upcoming funding opportunity for the Gabriella Miller Kids First Training and Outreach Core, aimed at enhancing pediatric research related to childhood cancer and congenital anomalies. This initiative seeks to engage researchers and patient communities to improve the utilization of Kids First data, ultimately leading to better-targeted therapies and interventions. The estimated total program funding is $800,000, with applications expected to be solicited in the future; interested parties are encouraged to prepare collaborative proposals. For further information, potential applicants can contact Concepcion R. Nierras, Ph.D., at 301-435-5840 or via email at concepcion.nierras@nih.gov.
    Continued Development of the Gabriella Miller Kids First Pediatric Data Resource Center (U2C Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a funding opportunity for the Continued Development of the Gabriella Miller Kids First Pediatric Data Resource Center through a Cooperative Agreement. This initiative aims to enhance the Pediatric Data Resource, focusing on expanding data sharing, providing training in cloud-based computational analysis, and facilitating data use for researchers with limited bioinformatics training, ultimately contributing to advancements in understanding childhood cancer and congenital anomalies. The estimated total program funding is $5,200,000, with applications not currently being solicited; however, potential applicants are encouraged to prepare collaborative projects in anticipation of the upcoming Notice of Funding Opportunity (NOFO), which is expected to be published by July 30, 2025, with a closing date for synopsis on October 30, 2025. For further inquiries, interested parties may contact Dr. Concepcion R. Nierras at 301-435-5840 or via email at concepcion.nierras@nih.gov.
    Natural History of Disorders Screenable in the Newborn Period (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Natural History of Disorders Screenable in the Newborn Period (R01 Clinical Trial Optional)" aimed at expanding knowledge of disorders that are currently or may become part of statewide newborn screening programs. This initiative seeks to gather comprehensive data on the natural history of these conditions to facilitate appropriate interventions for affected infants, improve diagnostic accuracy, and support the development of targeted treatments. The funding will assist in identifying biological mechanisms, understanding genetic diversity, and establishing data collection systems for longitudinal studies, emphasizing the importance of research in newborn screening. Interested applicants, including various educational and community organizations, can submit proposals with a maximum project period of five years, with the funding cycle opening on January 5, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-25-227.html.
    GREGoRi Innovation Projects (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is set to announce a funding opportunity titled "GREGoRi Innovation Projects (U01 Clinical Trial Optional)" aimed at soliciting applications for research on proof of concept studies that explore innovative strategies for identifying genes or variants associated with rare genetic disorders. This initiative seeks to advance beyond traditional DNA sequencing methods by incorporating emerging molecular technologies, such as multi-omics and RNA-seq, to enhance the understanding of these disorders. The funding will be provided through a cooperative agreement, with no cost-sharing requirement, and is particularly targeted at small businesses engaged in health-related research. Interested applicants should prepare for the anticipated Notice of Funding Opportunity (NOFO) publication in 2025, with applications due in 2026, and can reach out to Lisa H. Chadwick at lisa.chadwick@nih.gov or by phone at 301-435-7275 for further information.
    Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - Clinical Trial Optional)" aimed at promoting research and development of novel screening methods and therapeutic interventions for conditions identified through newborn screening. This initiative encourages innovative projects that generate preliminary data on both existing and potentially fatal genetic disorders, emphasizing the importance of early detection and intervention. The program is open to a wide range of eligible applicants, including higher education institutions, nonprofits, and governmental bodies, with a total funding ceiling of $275,000 over two years. Interested applicants should note that the submission deadlines begin on January 16, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    GREGoRi Data Coordination and Outreach Center (U01, Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the establishment of the GREGoRi Data Coordination and Outreach Center, aimed at advancing the Genomics Research to Elucidate the Genetics of Rare Disease (GREGoR) program. This initiative seeks to enhance the diagnosis of rare genetic disorders by developing innovative tools and analytical methods to identify causal genes and variants, with the center serving as the primary coordination hub for data and resources generated by the GREGoRi program. The total estimated funding for this cooperative agreement is $2 million, with one award anticipated, and applications are expected to be due in 2026 following the publication of the Notice of Funding Opportunity (NOFO) in 2025. For further inquiries, interested applicants can contact Lisa H. Chadwick at lisa.chadwick@nih.gov or by phone at 301-435-7275.
    Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)" aimed at advancing precision medicine for pregnant individuals, lactating persons, and children. This grant seeks to support innovative research that develops novel tools and technologies, enhances understanding of drug mechanisms, and improves therapeutic options for these populations, particularly those with disabilities. The initiative is part of the R21 Exploratory/Developmental Research Grants program, with a funding cap of $275,000 over a potential two-year period, and requires a Data Management and Sharing Plan as part of the application process. Interested applicants can find more information and submit inquiries via email at grantsinfo@nih.gov, with the application deadline set for May 7, 2026.
    Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders" (PAR-25-327), aimed at supporting Investigational New Drug (IND)-enabling studies and preparations for First-in-Human (FIH) clinical trials. This initiative focuses on advancing innovative gene-based therapies, such as oligonucleotides and viral vector approaches, for ultra-rare disorders affecting fewer than 6,000 patients, with an emphasis on projects that demonstrate robust proof of concept data and readiness for clinical trials. Eligible applicants include a wide range of organizations, including higher education institutions and various nonprofit and for-profit entities, with applications requiring detailed project planning and compliance with Good Manufacturing Practices (GMP). The application period opens on January 9, 2025, with a close date of October 8, 2027, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01 Clinical Trial Optional)" aimed at advancing precision medicine for pregnant individuals, lactating individuals, and children. This initiative seeks to support translational and clinical research that develops novel therapeutic tools, enhances understanding of drug mechanisms, and improves medication safety and efficacy for these vulnerable populations. The program emphasizes interdisciplinary collaboration to address unmet therapeutic needs and promote better health outcomes in maternal and pediatric medicine. Applications will be accepted starting January 5, 2025, with a closing date of May 7, 2026. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-110.html.